findmyKOL
Clinical trialNCT06115642Enrolling, by, invitationPhase 1Interventional

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

SponsorShanghai Henlius BiotechEnrollment367Advanced/Metastatic Malignant Solid Tumors
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Jie Wang, Dr.

    Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Xiangya Hospital Central South University

    Changsha, Hu'nan, China

Japan
  • Sendai Kousei Hospital

    Sendai, Miyagi, Japan

  • Kindai University Hospital

    Sayama, Osaka, Japan

  • Okayama University Hospital

    Okayama, Japan

  • Shizuoka Cancer Center

    Shizuoka, Japan

  • National Cancer Center Hospital

    Tokyo, Japan

United States
  • Stanford University

    Stanford, California, United States

  • Georgetown University

    Washington D.C., District of Columbia, United States

  • Md Anderson Medical Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
24 Nov 2023
Primary completion
30 Jun 2026
Completion
30 Nov 2027
Last update posted
29 May 2026
Registered enrollment
367
Registry id
NCT06115642

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.